top of page
Blog
Search
Update: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment
The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unme
NCF Team
Jan 26, 20241 min read
THESE FOUR LETTERS: PRRT (PART I)
An Overview of PRRT Peptide Receptor Radionuclide Therapy Original post April 2, 2019; Updated 12/17/2022 By now, you’ve probably heard...
NCF Team
Dec 17, 20227 min read
PRRT (PART II)
More about PRRT Peptide Receptor Radionuclide Therapy Original post April 24, 2019; Updated 12/17/2022 In our previous article, “ These...
NCF Team
Dec 17, 20223 min read
bottom of page